Article
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
Oncotarget - 1 Nov 2011
LaRochelle Olivier, Bertoli Sarah, Vergez François, Sarry Jean-Emmanuel, Mansat-De Mas Véronique, Dobbelstein Sophie, Dastugue Nicole, Strzelecki Anne-Claire, Cavelier Cindy, Creancier Laurent, Pillon Arnaud, Kruczynski Anna, Demur Cécile, Sarry Audrey, Huguet Françoise, Huynh Anne, Récher Christian, Delabesse Eric
Abstract excerpt
Mutations in DNMT3A encoding DNA methyltransferase 3A were recently described in patients with acute myeloid leukemia. To assess their prognostic significance, we determined the mutational status of DNMT3A exon 23 in 288 patients with AML excluding acute promyelocytic leukemia, aged from 18 to 65 years and treated in Toulouse University Hospital. A mutation was detected in 39 patients (13.5%). All DNMT3A exon 23+...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
